FIELD: pharmacology.
SUBSTANCE: invention relates to methods for obtaining compositions containing aflibercept in a medium with a chemically defined composition (CDC) and using chromatography to obtain certain variants of aflibercept.
EFFECT: expansion of the range of compositions against VEGF.
26 cl, 59 dwg, 58 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2795973C1 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2778325C1 |
| PROTEIN COMPOSITIONS AGAINST VEGF AND METHODS FOR THEIR PRODUCTION | 2020 |
|
RU2785994C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2016 |
|
RU2769470C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
